Phase 3 trials (Frias et al., 2021
Badve and colleagues conducted what's called a meta-analysis -- a large review of data from multiple studies, in this case 11 large-scale clinical trials of GLP-1s involving more than 85,000 people in all
Recent analysis by the American Academy of Actuaries suggested that the high cost of these medications, combined with the need for long-term use, could place upward pressure on 2025 health insurance premiums, particularly as more patients met clinical criteria for covered diagnoses
Accessed February 13, 2025
On one hand, research suggests that GLP-1 receptor agonists, including semaglutide, may provide some protection to the kidneys
Ali agreed with Cutler that the findings, while concerning, were unsurprising